At baseline, MASH-CKD had a lower GLP-2 response and a 2-fold higher postprandial LPS and NF-kB activation in MNCs than MASH patients without CKD, but similar remaining postprandial or fasting parameters. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatohepatitis.